Celgene Corp. has completed its acquisition of Receptos, Inc. for approximately $7.2 billion. The acquisition expands Celgene’s Inflammation & Immunology portfolio, adding Ozanimod, an oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to its pipeline of potential disease-altering medicines and investigational compounds.   Clinical studies of Ozanimod have demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative co...